Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

Dow Jones04-03

0841 GMT - Uncertainty remains across the pharmaceutical industry until there is better visibility around the potential impact of U.S. tariffs, Shore Capital analyst Sean Conroy says in a note. U.S. President Trump announced across-the-board 10% tariffs on Wednesday on all imports and a 20% tariff on EU goods which, for now, exempts pharmaceuticals. GSK confirmed that there would be no changes to its outlook, whereas AstraZeneca said it will assess the implications of Trump's tariff announcement and Roche said it would consider additional U.S. investments. Shore Capital anticipates that stock prices might remain weak until companies can quantify the potential impact of tariffs on earnings and revenue, Conroy says. GSK's shares are up 1.5%, while AstraZeneca's are up 1.6% and Roche's are down 2.1%. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

April 03, 2025 04:41 ET (08:41 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524284993?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-04-03 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524284993","market":"sg","top_or_hot":-1,"title":"Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0841 GMT - Uncertainty remains across the pharmaceutical industry until there is better visibility around the potential impact of U.S. tariffs, Shore Capital analyst Sean Conroy says in a note. U.S. President Trump announced across-the-board 10% tariffs on Wednesday on all imports and a 20% tariff on EU goods which, for now, exempts pharmaceuticals. GSK confirmed that there would be no changes to its outlook, whereas AstraZeneca said it will assess the implications of Trump's tariff announcement and Roche said it would consider additional U.S. investments. Shore Capital anticipates that stock prices might remain weak until companies can quantify the potential impact of tariffs on earnings and revenue, Conroy says.  GSK's shares are up 1.5%, while AstraZeneca's are up 1.6% and Roche's are down 2.1%. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2025 04:41 ET (08:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-03 16:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0841 GMT - Uncertainty remains across the pharmaceutical industry until there is better visibility around the potential impact of U.S. tariffs, Shore Capital analyst Sean Conroy says in a note. U.S. President Trump announced across-the-board 10% tariffs on Wednesday on all imports and a 20% tariff on EU goods which, for now, exempts pharmaceuticals. GSK confirmed that there would be no changes to its outlook, whereas AstraZeneca said it will assess the implications of Trump's tariff announcement and Roche said it would consider additional U.S. investments. Shore Capital anticipates that stock prices might remain weak until companies can quantify the potential impact of tariffs on earnings and revenue, Conroy says.  GSK's shares are up 1.5%, while AstraZeneca's are up 1.6% and Roche's are down 2.1%. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2025 04:41 ET (08:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2236285917.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524284993","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524284993","pubTimestamp":1743669660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0841 GMT - Uncertainty remains across the pharmaceutical industry until there is better visibility around the potential impact of U.S. tariffs, Shore Capital analyst Sean Conroy says in a note. U.S. President Trump announced across-the-board 10% tariffs on Wednesday on all imports and a 20% tariff on EU goods which, for now, exempts pharmaceuticals. GSK confirmed that there would be no changes to its outlook, whereas AstraZeneca said it will assess the implications of Trump's tariff announcement and Roche said it would consider additional U.S. investments. Shore Capital anticipates that stock prices might remain weak until companies can quantify the potential impact of tariffs on earnings and revenue, Conroy says.  GSK's shares are up 1.5%, while AstraZeneca's are up 1.6% and Roche's are down 2.1%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","GSK.UK":"葛兰素史克","AZN":"阿斯利康","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","GSK":"葛兰素史克","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4532":"文艺复兴科技持仓","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","03165":"华夏欧优股对冲","RHHBY":"罗氏控股"},"translate_title":"大型制药公司对美国关税风险仍不确定——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"AZN":0.9,"GSK":0.9,"GSK.UK":0.6,"RHHBY":0.9},"content_text":"0841 GMT - Uncertainty remains across the pharmaceutical industry until there is better visibility around the potential impact of U.S. tariffs, Shore Capital analyst Sean Conroy says in a note. U.S. President Trump announced across-the-board 10% tariffs on Wednesday on all imports and a 20% tariff on EU goods which, for now, exempts pharmaceuticals. GSK confirmed that there would be no changes to its outlook, whereas AstraZeneca said it will assess the implications of Trump's tariff announcement and Roche said it would consider additional U.S. investments. Shore Capital anticipates that stock prices might remain weak until companies can quantify the potential impact of tariffs on earnings and revenue, Conroy says.  GSK's shares are up 1.5%, while AstraZeneca's are up 1.6% and Roche's are down 2.1%. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 04:41 ET (08:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524284993"}